

California Tuberculosis Prevention and Control Objectives and Targets 2020-2024, by Strategy Area

California Targets

Objective	2020	2021	2022	2023	2024
Strategy 1: Diagnosis/Treatment of Persons with TB Disease					
1.1a TB Case Rate	5.1	4.6	4.2	4.0	3.9
1.1b US-Born Case Rate	1.2	1.1	1.1	1.1	1.0
1.1c Non US-Born Case Rate	15.7	14.0	12.8	12.2	11.6
1.1d African American Case Rate	2.7	2.5	2.3	2.2	2.1
1.1e Pediatric Case Rate	1.1	1.1	1.0	0.9	0.9
<i>1.1f Asian Case Rate</i>	<i>18.8</i>	<i>16.9</i>	<i>15.6</i>	<i>14.9</i>	<i>14.3</i>
<i>1.1g Hispanic/Latinx Case Rate</i>	<i>4.6</i>	<i>4.1</i>	<i>3.8</i>	<i>3.6</i>	<i>3.5</i>
1.2 Known HIV Status	90%	91%	92%	93%	94%
1.3 Laboratory Turnaround Time – Culture	67%	68%	70%	71%	72%
1.4 Laboratory Turnaround Time – NAAT	91%	93%	94%	95%	96%
1.5 Drug Susceptibility Result	97%	97%	98%	98%	99%
1.6 Sputum Culture Reported	95%	96%	96%	97%	98%
1.7 Recommended Initial Therapy	93%	94%	94%	94%	95%
1.8 Treatment Initiation	92%	94%	95%	97%	98%
1.9 Sputum Culture Conversion	73%	74%	75%	76%	77%
1.10 Completion of Treatment	90%	90%	91%	91%	92%
<i>1.11a Nucleic Acid Amplification Test Used – Smear-Positive TB</i>	<i>78%</i>	<i>79%</i>	<i>80%</i>	<i>80%</i>	<i>81%</i>
<i>1.11b Nucleic Acid Amplification Test Used – Smear-Negative TB</i>	<i>45%</i>	<i>47%</i>	<i>48%</i>	<i>49%</i>	<i>50%</i>
<i>1.12 Self-Administered Therapy</i>	<i>2.2%</i>	<i>2.1%</i>	<i>1.9%</i>	<i>1.7%</i>	<i>1.5%</i>
<i>1.13 Deaths with TB</i>	<i>8.2%</i>	<i>7.4%</i>	<i>6.7%</i>	<i>6.0%</i>	<i>5.3%</i>
Strategy 2A: Conduct contact investigations for infectious TB cases					
2A.1 Contact Elicitation	96%	96%	97%	97%	98%
2A.2 Contact Evaluation	86%	88%	89%	91%	92%
2A.3 Contact LTBI Treatment Initiation	72%	73%	75%	76%	77%
2A.4 Contact LTBI Treatment Completion	79%	80%	82%	84%	85%
2A.5 Data Reporting – ARPE	89%	89%	89%	89%	89%
Strategy 2B: Examination and treatment of immigrants and refugees with Class B notification					
2B.1 Immigrant/Refugee Evaluation Initiation within 30 Days	42%	49%	56%	62%	69%
2B.2 Immigrant/Refugee Evaluation Completion within 90 Days	36%	40%	45%	49%	54%
<i>2B.3 Immigrant/Refugee Evaluation Complete</i>	<i>58%</i>	<i>63%</i>	<i>68%</i>	<i>73%</i>	<i>77%</i>
2B.4 Immigrant/Refugee LTBI Treatment Initiation	62%	67%	71%	75%	78%
2B.5 Immigrant/Refugee LTBI Treatment Completion	59%	63%	67%	70%	74%
2B.6 Data Reporting – EDN	67%	72%	77%	82%	87%
Strategy 2C: Targeted testing and treatment of LTBI in high-risk populations					
<i>2C.1 Non US-Born Persons Tested for LTBI</i>	<i>TBD</i>	<i>TBD</i>	<i>TBD</i>	<i>TBD</i>	<i>TBD</i>
<i>2C.2 Non US-Born Persons Completing LTBI Treatment</i>	<i>TBD</i>	<i>TBD</i>	<i>TBD</i>	<i>TBD</i>	<i>TBD</i>
Strategy 4: Epidemiologic Surveillance and Response					
4.1 Data Reporting – RVCT	99%	99%	99%	99%	99%
4.2 Universal Genotyping	98%	98%	99%	99%	99%

ARPE = Aggregate Reports on Performance Evaluation – Contact Investigation

EDN = Electronic Disease Network

HIV = human immunodeficiency virus

LTBI = latent tuberculosis infection

NAAT = nucleic acid amplification test

RVCT = Report of Verified Case of Tuberculosis

TB = tuberculosis

US = United States

Notes: Objectives in regular font are NTIP indicators. Objectives in italics are California (non-NTIP) indicators